Please login to the form below

Not currently logged in
Email:
Password:

disease progression

This page shows the latest disease progression news and features for those working in and with pharma, biotech and healthcare.

Trial backs Inovio/Sanofi combo in hard-to-treat brain cancer

Trial backs Inovio/Sanofi combo in hard-to-treat brain cancer

no evidence of disease progression. ... little progress in developing new treatments for the disease, including with new cancer immunotherapies.

Latest news

More from news
Approximately 1 fully matching, plus 254 partially matching documents found.

Latest Intelligence

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimer’s ahead of a cure

    According to the study, the blood test is able to identify this protein 20 years before the symptoms of the disease start to present. ... Alzheimer’s R&D has had to diversify as companies and researchers become increasingly aware that the disease has a

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    applications in pharma and real-world ML/AI platforms for scalable disease diagnostics, progression and treatment. ... We’re going to work with the NHS to eliminate this disease in the UK.

  • The first, my last, my everything The first, my last, my everything

    In a widespread shift from volume to value, around 80% of molecules in development at present are in oncology or rare disease. ... In the past, industry has taken a traditional view of patient value, typically basing it on clinical outcomes and disease

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    other factors, may act on disease progression or influence responses to drugs. ... And there is scope to improve the lives of Alzheimer’s patients without slowing the progression of the disease, for example by hitting targets that improve cognition.

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Luc Truyen, Vice President, Neuroscience External Affairs at Janssen R&D said that failures in the field pointed towards a need to target Alzheimer’s disease earlier in its progression. ... Diseases include Alzheimer’s, dementia with Lewy bodies,

More from intelligence
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest appointments

  • PatientsLikeMe names Jason Johnson as head of R&D PatientsLikeMe names Jason Johnson as head of R&D

    Johnson will lead the company's research, data science and informatics teams, which focus on analysing and merging patient-reported data and other data types to develop models of disease progression ... and generate new insights about disease, treatments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics